Post-Exploitation in Medical Device Penetration Testing

Part of our medtech cybersecurity framework choice series (SPDF, JSP2, IEC 81001-5-1). For the full overview, start with JSP2 vs SPDF vs IEC 81001-5-1: Framework Pick.

Reviewed September 17, 2026

Getting initial access to a medical device tells a manufacturer very little on its own; what matters is what an attacker could do next. A tester who stops at the first foothold leaves the highest-impact questions unanswered: can this access reach the hospital network, can it survive a reboot, and what patient data or clinical function is actually exposed. Skipping post-exploitation work produces a report that looks thorough but misses the findings a manufacturer's risk file actually needs.

At the same time, post-exploitation testing on a device that may be connected to a patient carries real safety stakes that a typical IT penetration test does not. A pivot technique that is routine on a corporate laptop can crash an infusion pump or interrupt a monitor. This piece covers what post-exploitation testing looks like for medical devices: pivoting, persistence, exfiltration paths, the safety controls that bound the engagement, and how findings connect to security risk documentation reviewers expect to see.

Why This Matters

A penetration test that stops at initial access misrepresents the actual risk a device carries. Attackers who gain a foothold rarely stop there; they look for a path to higher-value systems, a way to survive a restart, and a channel to move data out. If a test does not simulate that behavior under authorized, scoped conditions, the resulting report cannot tell a manufacturer whether its network segmentation, logging, or monitoring would catch a real intrusion in progress.

For manufacturers, this connects directly to the FDA's expectation that cybersecurity risk be evaluated across the total product lifecycle, including how an exploited device could affect patient safety and the broader clinical environment. A post-exploitation finding, such as a successful pivot from a device's management interface into a hospital VLAN, is often the single piece of evidence that changes a risk score from acceptable to unacceptable. Without it, a risk file may understate the real exposure.

The stakes are different from a typical IT penetration test because many medical devices interact directly with patients. A technique that is safe to run against a server can cause a device to freeze, reboot, or deliver an incorrect therapy. This is why post-exploitation testing on medical devices requires explicit safety controls and rules of engagement agreed before testing starts, not improvised in the moment when a tester finds a promising path.

What Happens After Initial Access?

Initial access is the starting point, not the finding. Once a tester has a foothold, whether through a compromised credential, an exposed debug interface, or a vulnerable service, the post-exploitation phase asks what that foothold actually enables: further access, persistence, or data exposure.

This typically follows a structured sequence: situational awareness of the compromised system, privilege escalation if needed, then a decision about whether to pivot, persist, or move directly to data collection based on the scope agreed with the manufacturer. Each of these steps should be logged in real time, not reconstructed afterward from memory.

[KEY REQUIREMENT] Every post-exploitation action taken during a test must be pre-authorized in the scope document, including which pivot targets, persistence techniques, and data types are in bounds. Testers should not improvise beyond that scope even when a promising path appears mid-engagement.

How Does Pivoting Work from a Device into Clinical Networks?

Pivoting from a device answers whether a compromised device can be used as a launch point into the broader clinical network, which is often the most consequential question in the engagement. A device that sits on the same VLAN as clinical workstations, or that trusts a shared authentication domain, can turn a single-device compromise into a hospital-wide exposure.

Testers evaluate this by attempting authorized lateral movement from the device toward higher-value network segments, checking whether network segmentation, firewall rules, and access controls actually enforce the boundaries a manufacturer's architecture diagram claims exist. A finding here is not just "segmentation failed"; it needs to specify which segment was reached and by what path.

What Does Persistence Look Like on Embedded Targets?

Persistence on an embedded medical device is often more limited than on a general-purpose computer, and that limitation is itself worth documenting. Many embedded devices use read-only or signed firmware partitions that make traditional persistence techniques, such as planting a startup script, impossible without also compromising the update or signing process.

Where persistence is possible, common paths include writable configuration partitions, unsigned auxiliary firmware components, or persistence at the cloud and account level rather than on the device itself. A tester should confirm whether a reboot or factory reset actually clears the compromise, since a manufacturer's incident response plan depends on knowing whether that is true.

[KEY REQUIREMENT] A post-exploitation test must explicitly state whether persistence was achieved on the device, in supporting cloud infrastructure, or not at all, because this determines whether a field remediation can rely on a simple reboot or requires a full device recall and reflash.

What Are the Common Data Exfiltration Paths?

Data exfiltration testing maps how patient data, credentials, or device secrets could leave the environment once an attacker has access, not just whether the data exists. Common paths include unencrypted telemetry channels, cloud storage buckets with overly broad access, and local logs that capture more patient data than the device's stated data flow diagram accounts for.

See also: Medical Device Pen Testing Providers, Medical Device Robustnesss & Fuzz Testing, and Scoping a Medical Device Penetration Test: A Practical Guide.

Testers also check whether large or unusual data transfers would actually be detected, since a manufacturer's monitoring plan is only as good as the paths it covers. A finding that data could leave through a channel the manufacturer had not documented is often a bigger risk factor than the exfiltration itself, because it means the risk assessment missed that data flow entirely.

Checklist of paths to test:

• Telemetry and diagnostic channels to cloud backends
• Local log files and crash dumps that may retain patient identifiers
• Removable media or service ports used by field technicians
• API responses that return more data than the requesting role needs

What Evidence Belongs in the Report?

A post-exploitation report needs to document the path taken, the systems reached, the data or capability exposed, and whether the activity would have been detected, not just a list of techniques attempted. Each finding should reference the specific security requirement or risk item it affects, so the manufacturer can route it directly into their risk management file rather than treating it as a standalone narrative.

Evidence should include timestamps, the exact commands or requests used within the agreed scope, and screenshots or logs proving the outcome, since a reviewer or auditor needs to be able to trace the claim back to something verifiable. Retest results after remediation belong in the same report structure so the full lifecycle of the finding is visible in one place.

[KEY REQUIREMENT] A post-exploitation report must state explicitly that a passing test does not attest the manufacturer's design inputs were met; that verification remains the manufacturer's own responsibility, using the test findings as one input among several.

What Safety Controls and Rules of Engagement Apply to Patient-Connected Devices?

Safety controls take priority over demonstrating further compromise whenever a device may be connected to, or capable of affecting, a patient. Rules of engagement must define stop conditions in advance: what device states trigger an immediate halt, which techniques are excluded entirely, and who has authority to pause the test.

Testing against live patient-connected devices is generally avoided; instead, testers work against bench units, clinical simulators, or isolated lab environments configured to match production as closely as possible. Where a live or clinical environment must be used, a clinical safety observer and a documented rollback plan should be part of the engagement, not an afterthought.

How Blue Goat Cyber Approaches This

Blue Goat Cyber scopes post-exploitation activity around the manufacturer's actual architecture and risk file, rather than running a generic playbook against every device. That means agreeing on pivot targets, persistence boundaries, and stop conditions before testing starts, and mapping every finding back to a specific security requirement so it can be verified against the manufacturer's own design inputs. Engagements that involve potential patient-connected states include documented safety controls and, where warranted, use bench or simulated environments instead of live devices. This work is typically scoped as part of medical device penetration testing engagements.

Frequently Asked Questions

Is post-exploitation testing safe to run on a device that could be connected to a patient?

Direct testing on a live patient-connected device is generally avoided. Testers instead use bench units or clinical simulators configured to match production, with pre-agreed stop conditions and a rollback plan in place if the environment must be closer to live conditions.

What is the difference between initial access and post-exploitation in a device test?

Initial access confirms a tester could get into the device or its supporting system, while post-exploitation determines what that access actually enables, such as reaching other network segments, surviving a reboot, or exposing data. Post-exploitation findings usually carry more weight in a risk assessment because they show real impact.

Can persistence actually be achieved on a medical device?

It depends on the device's firmware architecture. Devices with signed, read-only firmware partitions often resist traditional persistence, while writable configuration areas or supporting cloud accounts can retain a compromise; a test should state clearly which was true for the device under evaluation.

How do exfiltration findings connect to a manufacturer's risk documentation?

Each exfiltration path identified during testing should map to a specific data flow or asset entry in the manufacturer's security risk management file. If a path is found that was not documented, that gap itself becomes a finding, since it means the risk assessment did not account for that data flow.

Does a clean post-exploitation test mean the device is fully secure?

No test result should be read as a guarantee of security or of a specific FDA outcome. A clean result means the specific techniques and scope tested did not succeed; the manufacturer is still responsible for verifying that its full set of security requirements was met.

CTA

If your device testing program stops at initial access, you may be missing the findings that matter most for your risk file. Book a discovery call to scope a post-exploitation assessment that fits your device's safety profile.